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DOI 10.1016/j.chembiol.2010.10.004Streptococcus pneumoniae certainly
can’t be trusted. Rather than live in the
soil or on kitchen counters, this microbe
makes its home among neighborly
bacteria inhabiting the nasopharynx of
preschool children. Most of the time,
colonies hang around for a while and
then harmlessly disappear. Other times,
S. pneumoniae escapes the safe borders
of this tiny neighborhood, travels to the
inner ear, lungs, or bloodstream, and
sparks a variety of illnesses ranging from
otitis media to meningitis and pneumonia.
Of these invasive pneumococcal dis-
eases, as they’re called, pneumonia is
the largest public health threat. The World
Health Organization describes pneu-
monia as the leading cause of death in
children worldwide, accounting for nearly
two million deaths each year. S. pneumo-
niae is the major bacterial pneumonia
pathogen.S. pneumoniaewon’t let vaccine designers off the hook so easily.Scientists can tell the serotypes of
S. pneumoniae apart by the polysaccha-
rides that coat the capsule. To date,
more than 90 serotypes have been identi-
fied. Not all 90 serotypes cause disease,
but those that do differ worldwide.
The only weapons against pneumo-
coccal pneumonia are antibiotics and
vaccines. Children under 5 years of age
and adults over 65 are most susceptible
to pneumonia and need the boost from
a vaccine. The PPSV23 is a polysaccha-
ride vaccine recommended for adults
over 65 and for younger adults who are
smokers and who take immune-sup-
pressing drugs. That vaccine won’t work
in young children, though, because their
immune systems can’t make antibodies
to the polysaccharide coating on the
bacteria’s capsule. Making a conjugate
vaccine by chemically linking the sugars
to a protein makes the complex recogniz-
able to the immune systems of infants and
young children. Babies’ immune systems
recognize the protein, and while their
immune systems recognize the protein,the systems recognize the polysaccha-
rides as well and induce immunity to both.
‘‘Conjugate vaccines changed the
infectious disease world; they totally
change the body’s immune response,’’
says Edwin L. Anderson, M.D., a vaccine
expert at Saint Louis University in St.
Louis, Missouri. ‘‘If you conjugate the
polysaccharide to a protein carrier, then
a body’s response is a T cell response,
meaning it’s cell-mediated immunity and
with a long-term response, because
T cells have a memory.’’
In 2000, Wyeth (now Pfizer) introduced
a conjugate vaccine against the seven
most virulent and prevalent serotypes: 4,
6B, 9V, 14, 18C, 19F, and 23F. In the
United States, 80% of pneumococcal
disease in children 5 years of age is
caused by those seven serotypes. Over
the past decade, pneumococcal disease
caused by serotypes covered in PCV 7has dropped. Since children are the
ones that carry S. pneumoniae in their
nasal passages, stopping these sero-
types in vaccinated children helps protect
people of all ages via herd immunity. In
2010, Pfizer introduced PCV 13, which
covers the original seven serotypes and
six more. The vaccine is licensed in
infants and is currently in phase III testing
for use in adults.
It’s Complicated
With S. pneumoniae, nothing proves
simple. Since the introduction of PCV 7,
other strains not covered by the vaccine
are emerging as problems. The most
notorious is 19A, which is now the most
prominent pneumococcal serotype in the
United States. ‘‘It makes sense that
we’re seeing strains not covered in the
vaccine,’’ says Rachel Orsheln, M.D., an
infectious disease specialist at Washing-
ton University in St. Louis, Missouri. ‘‘We
knew that 19A was a strain that caused
invasive pneumococcal disease, and
that strain is drug resistant. We justChemistry & Biology 17, October 29, 2010 ªthought the strains in the vaccine would
provide some cross-protection; as it
turned out, it didn’t.’’
The hope for cross-protection and the
real breakthrough for the pneumonia
vaccine came in the 1980s with the devel-
opment of a conjugate vaccine for Hae-
mophilus influenzae type b. Since the
introduction of that vaccine, all serotypes
(A through F) have disappeared. ‘‘That
organism startled everyone because that
disease has been eradicated in every
country where vaccine was introduced
and there was no replacement with other
serotypes,’’ says Steve Black, M.D., of
Cincinnati Children’s Hospital Medical
Center, in Ohio.
Haemophilus influenzae type b vaccine
helped boost confidence among vaccine
researchers as to how well a conjugate
vaccine could work against pneumo-
coccal diseases. The challenge in de-
signing the first pneumococcal vaccine
was choosing the serotypes that cause
the majority of disease and then making
conjugates for all seven serotypes individ-
ually to proteins in such a manner that
babies could respond to all seven, says
Peter Paradiso, Ph.D., vice president of
new business and scientific affairs at
Pfizer. ‘‘This was a big step going from
a vaccine that had one serotype to
a vaccine that had seven,’’ he says.
Paradiso and his colleagues hoped that
PCV 7 would also confer cross-protection
against serotypes that were similar in
polysaccharide composition just as the
Haemophilus influenzae type b vaccine
did. However, serotypes of Haemophilus
influenzae type b are mostly clones of
one another and the genome is stable,
so stopping one serotype put an end to
them all. This is why the vaccine for
tetanus toxin has been stable as a vaccine
candidate for so many years, explains
Black.
S. pneumoniae won’t let vaccine
designers off the hook so easily. To
understand why, think of all bacteria as
sitting along a spectrum from organisms
that don’t undergo any transformation to
organisms that do. If you put the pneumo-
coccus on that spectrum, it’s much more2010 Elsevier Ltd All rights reserved 1043
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b, explains Black: ‘‘You can guess that
by the fact that there are so many sero-
types and they change over time.’’ Mix in
the dynamics of antibiotic use and
vaccines and a dynamic epidemiology
emerges. S. pneumoniae exchanges
genetic information from one serotype to
the other. After such an exchange, patho-
genic serotypes will put on the cloak of
less pathogenic serotypes and cause
disease. ‘‘That’s what natural selection is
all about. Unlike the dodo bird, which
couldn’t sprout wings and became
extinct, the pneumococcus is not intent
on that happening,’’ says Black.
Vaccine developers have to adapt as
well. Nearly as soon as the PCV 7 vaccine
was unveiled in 2000, Wyeth began
working on PCV 13. Now, two companies
have pneumococcal vaccines with more
than seven serotypes. GlaxoSmithKline
has a new vaccine called Synflorix that
protects against ten serotypes (1, 4, 5,
6B, 7F, 9V, 14, 18C, 19F, and 23F).
Pfizer’s Prevnar 13 includes the original
seven in the first vaccine, plus 1, 3, 5,
6A, 7F, and 19A.
Pfizer’s Paradiso says, ‘‘We didn’t say
‘we have seven let’s just add six more.’
We wanted to make this vaccine more
worldwide so we included serotypes1
and 5, which are prevalent in sub-Saharan
Africa and can be epidemic. We added 6A
and 19A, which brought us up to eleven
serotypes. Then, worldwide data indi-
cated that 3 and 7F were important.’’
Protein Targets and Beyond
Even with the introduction of a 13-valent
vaccine, other serotypes will emerge,
because that’s what serotypes do. Over
time, the incidence of serotypes rises
and falls in different parts of the world.
Black has a graph in a recent commentary
published in the Pediatric Infectious
Disease Journal that tracks the change
in serotypes over the last 29 years in
Spain. Some serotypes can emerge as
new clones and spread in months (Black,1044 Chemistry & Biology 17, October 29, 202010). ‘‘Given air travel and the way
people move around these days, time
frame is compressed,’’ says Black.
Factor in the decade spent by pharma-
ceutical companies developing pneumo-
coccal vaccines and then shepherding
them through the regulatory process and
the fact that vaccines can only protect
against a given number of serotypes,
and serotypes like 19A can easily surface.
‘‘These vaccines, in my opinion, won’t
solve thewhole issue. Everyone is search-
ing very hard for alternative strategies,
including common proteins to all pneu-
mococci.Wewill have to go to these strat-
egies. Conjugated vaccines will buy us
time, but no more,’’ says Elizabeth
Sanders, M.D., Ph.D., a clinical scientist
in the Netherlands.
Sanders got started in clinical research
because she sees so many children in her
medical practice with otitis media and
respiratory tract infections. She and her
colleagues undertook a post hoc analysis
of a randomized controlled trial in the
Netherlands that aimed to see whether
reducing the dose schedule would delay
colonization with serotype 19A. Antibiotic
use in the Netherlands is relatively low
compared to the United States, so
Sanders figured her study would prove
the rise in 19A could be attributed to
PCV 7 and not antibiotics. The study pub-
lished recently in JAMA showed that
infants in the reduced dosage group
were more likely to have serotype 19A in
their nasopharynx, so PCV 7 pressed for
colonization with 19A (van Gils et al.,
2010).
For at least the past 10 years, scientists
have looked beyond conjugate vaccines
and have searched for proteins common
to all serotypes. One protein may not be
enough, says Paradiso, and may need to
be added to a conjugate vaccine.
Because S. pneumoniae are such change
artists, any protein could also change as
the genomes change. Thus far, none of
the protein vaccines has entered clinical
trials.10 ª2010 Elsevier Ltd All rights reservedAs scientists deal with organisms that
are smarter and smarter in terms of their
ability to adapt, scientists need to adapt
their approach as well. Black supports
a solution that he describes as controver-
sial because it’s new. If, for example,
serotype 2, which is most common in
Bangladesh, suddenly took off world-
wide, a pneumonia epidemic could occur
because no current vaccine contains that
serotype. The chemistry for making a new
conjugate may take a bit over 1 year.
However, the toxicity testing in animals
and the subsequent clinical trials bring
the process to 10 years. This time frame
could be shortened if vaccine manufac-
turers could switch out, say, serotype 2
with a serotype that wasn’t such
a problem at the time and then simply
using the vaccine.
Such an effort is already in place for the
influenza vaccine, which changes every
year in composition but is not viewed as
an entirely new vaccine, which 13-valent
Prevnar was, says Black. If the influenza
vaccine had to undergo regulatory testing
every time the vaccine changed, 10 years
would be required to roll out a new
vaccine that would always be a decade
behind. ‘‘We’re going to have to change
our frame of reference in terms of devel-
opment of regulatory controls to allow
for more rapid response to changes, or
we’ll always be behind the eight ball,’’
says Black.REFERENCES
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